摘要
目的观察以吉西他滨为主的联合化疗方案治疗对蒽环类和紫杉类均耐药的转移性乳腺癌的疗效和不良反应。方法我院从2006年1月～2008年12月分别采用吉西他滨联合顺铂(GP)、异环磷酰胺(GI)或希罗达(GX)方案治疗蒽环类和紫杉类均耐药的转移性乳腺癌74例,21天为1个周期,中位化疗周期数为4个。结果本组完全缓解(CR)1例(1%),部分缓解(PR)21例(30%),稳定(SD)35例(50%),进展(PD)13例(19%),总有效率(RR=CR+PR)为31%,临床获益率(CR+PR+SD>6个月)为53%,中位疾病进展时间(TTP)5个月,1年生存率为56.6%,2年生存率为34.8%,中位生存期为15个月。三组化疗方案间疗效无统计学差异。无化疗相关死亡病例,主要不良反应为骨髓抑制及胃肠道反应。结论以吉西他滨为主,联合顺铂、异环磷酰胺或希罗达方案对蒽环类和紫杉类均耐药的转移性乳腺癌有较好的疗效,不良反应可耐受,为有效的解救方案。
Objective To evaluate the efficacy and safety of chemotherapy of gemcitabine-based combination chemotherapy in the treatment of the anthracyeline and taxane-resistant metastatic breast cancer. Methods From January 2006 to December 2008, 74 patients with anthracycline and taxane-resistant metastatic breast cancer were treated with gemcitabine combined with eisplatin （GP） , ifosfamide （GI） , or capecitabine （ GX）, respectively. Twenty-one days for a cycle, with a median number of chemotherapy cycle of 4. Results The outcmes included ： complete remission （ n = 1 , 1%）, partial remission （n=21, 30%）, stability （n=35, 50%）, and disease progression （n=13, 19%）. The total response rate （ RR = CR ＋ PR） was 31%, clinical benefit rate （ CR ＋ PR ＋ SD greater than 6 months） was 53%, median time to disease progression （ TTP ） was 5 months, 1-year survival rate was 56. 6% , 2-year survival rate was 34. 8% , with a median survival time of 15 months. The efficacy among these three different chemotherapy regimens was not significantly different. No patient died due to chemotherapy. The main toxicity was myelosuppression and gastrointestinal reactions. Conclusion Gemcitabine combined with cisplatin or ifosfamide or capeeitabine is active in the treatment of anthracycline and taxane-resistant metastatic breast cancer with acceptable toxicity, and may be an effective salvage therapy.
出处
《癌症进展》
2010年第1期80-83,共4页
Oncology Progress
关键词
晚期乳腺癌
耐药
吉西他滨
疗效
不良反应
advanced breast cancer resistance gemcitabine effect toxicity
